Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN E BECKER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1487897146
CMS profile
491336
Location
BRENTWOOD, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,670.09

76 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,670.09 76

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN E BECKER

NPI 1487897146 · CMS profile ID 491336

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

BRENTWOOD, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487897146?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN E BECKER, NPI 1487897146, CMS profile ID 491336. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487897146?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JONATHAN E BECKER, NPI 1487897146, CMS profile ID 491336. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487897146?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JONATHAN E BECKER, NPI 1487897146, CMS profile ID 491336, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1487897146?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

76 matching records · $1,670.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 76 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 76.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Axsome Therapeutics, Inc. $25.6012/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235673328 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $31.1812/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254968 CMS
Alkermes, Inc. $16.8212/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222445080 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $30.9512/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254966 CMS
ABBVIE INC. $12.7412/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201490651 CMS
Noven Therapeutics, LLC $13.5912/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240401006 CMS
Axsome Therapeutics, Inc. $8.0011/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235625378 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $24.4811/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254964 CMS
Alkermes, Inc. $32.1111/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222445078 CMS
ABBVIE INC. $16.5711/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201490649 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7.3511/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254962 CMS
Janssen Pharmaceuticals, Inc $23.8711/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174890875 CMS
E.R. Squibb & Sons, L.L.C. $22.1911/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184560925 CMS
Axsome Therapeutics, Inc. $25.7210/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235624280 CMS
Alkermes, Inc. $29.9710/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222445076 CMS
ABBVIE INC. $12.5310/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201490647 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $14.5610/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254960 CMS
Axsome Therapeutics, Inc. $10.9310/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235562743 CMS
Janssen Pharmaceuticals, Inc $24.4110/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174891021 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $26.8009/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254958 CMS
ABBVIE INC. $2.9209/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201490643 CMS
ABBVIE INC. $2.9609/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201490645 CMS
Otsuka America Pharmaceutical, Inc. $22.9609/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227292913 CMS
Alkermes, Inc. $22.4509/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222445074 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8.2009/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254956 CMS
Janssen Pharmaceuticals, Inc $22.8309/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174890986 CMS
Otsuka America Pharmaceutical, Inc. $22.4408/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227292911 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $30.8008/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254954 CMS
Axsome Therapeutics, Inc. $26.0808/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235485627 CMS
Alkermes, Inc. $18.0508/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222445072 CMS
Supernus Pharmaceuticals, Inc. $22.6208/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244911313 CMS
Axsome Therapeutics, Inc. $30.0108/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235484859 CMS
ABBVIE INC. $8.0208/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201490641 CMS
ABBVIE INC. $22.1207/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201490639 CMS
Noven Therapeutics, LLC $13.5407/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240401008 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $23.6007/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254952 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $31.6207/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254950 CMS
Axsome Therapeutics, Inc. $25.6707/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235432610 CMS
Axsome Therapeutics, Inc. $20.2506/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235310389 CMS
Otsuka America Pharmaceutical, Inc. $23.6506/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227292909 CMS
ABBVIE INC. $6.1706/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201490637 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $33.1806/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254948 CMS
ABBVIE INC. $21.8606/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201490635 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $20.3406/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254946 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $28.6005/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241254944 CMS
ABBVIE INC. $19.1505/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201490633 CMS
Alkermes, Inc. $27.0505/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222445070 CMS
E.R. Squibb & Sons, L.L.C. $26.0605/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184560859 CMS
Axsome Therapeutics, Inc. $31.6305/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235736966 CMS
ABBVIE INC. $5.8705/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201490631 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $345.98 19
PY2022 $826.92 36
PY2023 $1,331.96 59
PY2024 $1,607.64 70
PY2025 $1,670.09 76

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $39,317.70 67
PY2024 Principal investigator $7,425.00 10
PY2023 Principal investigator $124,342.43 76
PY2022 Principal investigator $67,497.05 56
PY2021 Principal investigator $16,939.08 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

56 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 LivaNova USA, Inc. $12.24 12/23/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172269
Principal investigator 1 LivaNova USA, Inc. $74.36 12/23/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172276
Principal investigator 1 LivaNova USA, Inc. $12.24 12/23/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172295
Principal investigator 1 LivaNova USA, Inc. $2,791.27 12/16/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172175
Principal investigator 1 LivaNova USA, Inc. $2,419.70 12/01/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172157
Principal investigator 1 LivaNova USA, Inc. $60.84 12/01/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172251
Principal investigator 1 LivaNova USA, Inc. $5,510.03 11/23/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172189
Principal investigator 1 LivaNova USA, Inc. $19.44 11/23/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172283
Principal investigator 1 LivaNova USA, Inc. $2,120.64 11/03/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172163
Principal investigator 1 LivaNova USA, Inc. $996.88 10/26/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172195
Principal investigator 1 LivaNova USA, Inc. $60.84 10/26/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172289
Principal investigator 1 LivaNova USA, Inc. $2,918.14 10/20/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172181
Principal investigator 1 LivaNova USA, Inc. $9.72 10/13/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172265
Principal investigator 1 LivaNova USA, Inc. $1,595.01 10/11/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172169
Principal investigator 1 LivaNova USA, Inc. $86.90 10/11/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942172257
Principal investigator 1 LivaNova USA, Inc. $1,450.01 09/28/2022 Non-covered Recipient Entity
NORTHPOINTE PSYCHIATRY PA
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172009
Principal investigator 1 LivaNova USA, Inc. $6,053.78 09/22/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172003
Principal investigator 1 LivaNova USA, Inc. $12.24 09/22/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172119
Principal investigator 1 LivaNova USA, Inc. $60.84 09/22/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172125
Principal investigator 1 LivaNova USA, Inc. $9.72 09/22/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172131
Principal investigator 1 LivaNova USA, Inc. $2,401.58 09/09/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942171997
Principal investigator 1 LivaNova USA, Inc. $4,694.40 09/07/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942171991
Principal investigator 1 LivaNova USA, Inc. $12.24 08/19/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172095
Principal investigator 1 LivaNova USA, Inc. $60.84 08/19/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172101
Principal investigator 1 LivaNova USA, Inc. $9.72 08/19/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172107
Principal investigator 1 LivaNova USA, Inc. $13.32 08/19/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172113
Principal investigator 1 LivaNova USA, Inc. $13.32 08/19/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172301
Principal investigator 1 LivaNova USA, Inc. $9.72 08/19/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172307
Principal investigator 1 LivaNova USA, Inc. $60.84 08/11/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172089
Principal investigator 1 LivaNova USA, Inc. $12.24 08/04/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172063
Principal investigator 1 LivaNova USA, Inc. $60.84 08/04/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172069
Principal investigator 1 LivaNova USA, Inc. $9.72 08/04/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172075
Principal investigator 1 LivaNova USA, Inc. $13.32 08/04/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172081
Principal investigator 1 LivaNova USA, Inc. $13.32 08/04/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172313
Principal investigator 1 LivaNova USA, Inc. $5,120.34 07/27/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942171629
Principal investigator 1 LivaNova USA, Inc. $12.24 07/27/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172138
Principal investigator 1 LivaNova USA, Inc. $60.84 07/27/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172145
Principal investigator 1 LivaNova USA, Inc. $9.72 07/27/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942172151
Principal investigator 1 LivaNova USA, Inc. $9.72 07/27/2022 Non-covered Recipient Entity
PSYCHCARE CONSULTANTS RESEARCH
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942175903
Principal investigator 1 LivaNova USA, Inc. $1,141.88 06/30/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942171453
Principal investigator 1 LivaNova USA, Inc. $262.81 06/30/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942171459
Principal investigator 1 LivaNova USA, Inc. $670.63 06/16/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942171437
Principal investigator 1 LivaNova USA, Inc. $5,120.35 06/09/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942171431
Principal investigator 1 LivaNova USA, Inc. $82.80 06/02/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942171471
Principal investigator 1 LivaNova USA, Inc. $4,667.20 05/25/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942171443
Principal investigator 1 LivaNova USA, Inc. $361.44 05/19/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942171477
Principal investigator 1 LivaNova USA, Inc. $13.32 05/19/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942171483
Principal investigator 1 LivaNova USA, Inc. $4,386.27 05/05/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942171425
Principal investigator 1 LivaNova USA, Inc. $163.13 03/31/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942171307
Principal investigator 1 LivaNova USA, Inc. $308.13 03/17/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942171289
Principal investigator 1 LivaNova USA, Inc. $145.00 03/10/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942171269
Principal investigator 1 LivaNova USA, Inc. $1,141.88 02/23/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942171295
Principal investigator 1 LivaNova USA, Inc. $4,440.64 02/17/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942171283
Principal investigator 1 LivaNova USA, Inc. $2,220.32 02/10/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942171263
Principal investigator 1 LivaNova USA, Inc. $616.25 01/25/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942171301
Principal investigator 1 LivaNova USA, Inc. $2,881.88 01/12/2022 Non-covered Recipient Entity
NEUROSCIENCE AND TMS TREATMENT CENTER
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942171275